---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-267486"
form_type: "8-K"
ticker: "IRIX"
cik: "0001006045"
company_name: "IRIDEX CORP"
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T01:44:18.601842+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# IRIDEX withdraws FY2023 guidance after Medicare LCD restricts glaucoma reimbursement

## Summary
- WPS Medicare LCD effective Dec 24, 2023 will likely limit cyclophotocoagulation coverage to only refractory glaucoma patients meeting strict criteria.
- Company withdrawing previously announced 2023 annual guidance due to uncertainty from the LCD.
- WPS jurisdiction covers ~8% of US glaucoma probe sales; similar MAC actions could impact majority of US glaucoma revenue.
- IRIDEX plans to appeal LCD, engage with MACs, and initiate a clinical study to meet LCD evidence requirements.
- Outside US (50% of glaucoma revenue) not materially impacted by the LCD.

## SEC filing metadata
- accession: 0001193125-23-267486
- form_type: 8-K
- ticker: IRIX
- cik: 0001006045
- company_name: IRIDEX CORP
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006045/000119312523267486/0001193125-23-267486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006045/000119312523267486/d533658d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-267486
- JSON: https://secwatch.observer/filing/0001193125-23-267486.json
- Plain text: https://secwatch.observer/filing/0001193125-23-267486.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.